Hyperliquid Founder Addresses Revenue Prioritization Concerns
- Jeff Yan addresses trader concerns about Hyperliquid’s revenue model.
- Hyperliquid focuses on benefiting users through ADL.
- Potential profitability impact for users highlighted.
Hyperliquid prioritizes revenue over trader concerns by employing an Automatic Deleveraging (ADL) mechanism that shifts profits to users and mitigates risk. Founder Jeff Yan clarified the model, emphasizing its impact, including token buybacks worth $645 million.
Jeff Yan, founder of Hyperliquid , recently clarified the platform’s approach to revenue, addressing trader concerns regarding its revenue model. Yan emphasized that Hyperliquid aims to benefit users through its Automatic Deleveraging (ADL) mechanism.
Amid questions about Hyperliquid’s focus on protocol revenue over traders, this clarification holds significance for users and market observers. The response showcases transparency over profit distribution.
The recent focus by Hyperliquid on its revenue model sparked responses, especially concerning the Automatic Deleveraging mechanism. Jeff Yan clarified that this model generates profits while mitigating risks, benefiting users with net financial gains.
In his statements, Yan addressed misconceptions that suggested Hyperliquid prioritized protocol revenue. He used platforms like X to emphasize that their mechanism is designed for user profit, particularly during high liquidation events.
Immediate market reactions were mixed, with some praising the platform’s transparency and others concerned about potential risk exposure. Hyperliquid’s decisions continue to impact user confidence and the broader DeFi ecosystem.
“The ADL event on October 10th generated hundreds of millions of dollars in net profits for users.” — Jeff Yan, Founder, Hyperliquid
Financial implications involve potential shifts in user trust and investment strategies. The platform’s mechanisms could affect DeFi market stability and user engagement, particularly with the ongoing focus on profit distribution.
With Hyperliquid’s stance clarified, industry participants are keenly observing the financial and technological outcomes. Historical trends suggest that similar mechanisms have led to user skepticism but also potential profitability, indicating a foundational shift in how DeFi platforms engage traders.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Bitcoin’s Latest Price Drop and What It Means for Crypto Investors: Addressing Systemic Threats and Regulatory Ambiguity in the Market After 2025
- Bitcoin's 2025 price crash from $126k to $92k exposed systemic risks in leveraged crypto markets, with $9.89B in liquidations triggered by macro shocks and thin liquidity. - Regulatory clarity via 2025 acts (GENIUS/CLARITY) boosted adoption but coexisted with geopolitical tensions and fragmented global standards, creating inconsistent risk environments. - Institutional Bitcoin demand surged through ETFs ($220B inflow in November 2025), contrasting with retail caution post-crash, as leverage risks and reg

AAVE rises 7.61% as Aave expands its CoW integration, introducing MEV-protected swaps and flash loans based on user intent
- Aave integrates CoW Protocol's solver network across all swap features, enhancing execution efficiency and security through batch-auction systems. - The partnership introduces intent-based flash loans, enabling advanced users to execute complex DeFi transactions with reduced gas fees and MEV risks. - Aave plans to expand intent-driven products beyond swaps and loans, aiming to offer programmable tools for sophisticated DeFi strategies while maintaining accessibility. - Despite a 7.61% 7-day price rise, A

LUNA Surges 20% in a Day Amid Ongoing Terra Network Upgrade
- LUNA surged 20% in 24 hours to $0.0868 as Terra network prepares a major upgrade on Dec 8, 2025. - Binance temporarily halted LUNA deposits/withdrawals during the upgrade to ensure protocol stability. - Adverum Biotech reported 90% reduced anti-VEGF injections in LUNA trial for wet AMD, with Phase 3 enrollment nearing completion. - The upgrade and biotech results highlight LUNA's dual impact on crypto markets and medical innovation potential.

FINRA: Younger Investors Keep Betting on Crypto and Meme Stocks